Abstract
Abstract. Normal human epithelial cell cultures exhibit a limited (although different between tissues) lifespan in vitro. In previous studies, urothelial cell cultures were immortalized using retroviral transformation with human papillomavirus type 16 E6 and E7 genes, in undefined culture systems containing serum or bovine pituitary extract. Objective: Due to the variability of results in such systems, we instead developed a procedure for the immortalization of urothelial cells using a defined, serum‐free culture system. Method and results: Immortalization through retroviral transformation with human papillomavirus type 16 E6 and E7 was successful, and transformation of urothelial cells conferred an extended over normal lifespan and restored telomerase activity. Transformed cells retained typical morphology and exhibited a similar growth rate, cytokeratin immunoreactivity pattern, and response to growth factors as observed in untransformed cells. Karyotype analysis revealed a gradual accumulation of genetic mutations that are consistent with previously reported mutations in epithelial cells transformed with human papillomavirus type 16 E6 and E7. Conclusion: The ability to extend the in vitro lifespan of cells holds the potential to reduce the continuous need for tissue samples and to enable complete investigations with one cell line.
INTRODUCTION
In vitro cultures of normal human cells proliferate for a limited number of population doublings before entering replicative senescence (Hayflick & Moorhead 1961). While the exact mechanism triggering this senescence is yet to be elucidated, a current hypothesis is that cells enter senescence when telomeres, which shorten with successive cell divisions, reach a critically short threshold length (Harley et al. 1990) due to loss of telomerase function (Vaziri & Benchimol 1998). This hypothesis is supported by studies that have shown that exogenous expression of human telomerase reverse transcriptase (hTERT) restores telomerase activity and confers an extended lifespan in several types of human cells (Bodnar et al. 1998; Yang et al. 1999; Forsythe et al. 2002). Restoration of telomerase is not sufficient to immortalize some types of cells, however, suggesting that telomere shortening alone cannot completely explain the replicative lifespan limit (Kiyono et al. 1998; Dickson et al. 2000; O’Hare et al. 2001; Di Donna et al. 2003). This disparity suggests there are fundamental differences in the control of senescence in various cell types.
In some epithelial cell types, including keratinocytes (Kiyono et al. 1998; Dickson et al. 2000), mammary epithelial cells (Brenner et al. 1998; Kiyono et al. 1998; Romanov et al. 2001), prostate epithelial cells (Jarrard et al. 1999) and urothelial cells (Puthenveettil et al. 1999), there is evidence of an association between senescence and the increased expression and accumulation of p16INK4A . Recent studies have shown that loss of p16 function does not extend urothelial cell lifespan in cultures derived from adult tissue specimens (Shaw et al. 2005; Chapman et al. 2006), but does extend lifespan in cultures derived from child tissue specimens (Chapman et al. 2006). Thus, the exact relationship between p16 accumulation and senescence in urothelial cell cultures remains unknown. It has been reported that the immortalization of some keratinocytes and epithelial cells requires a combination of telomerase activity restoration and a disruption in the retinoblastoma tumour suppressor protein (RB) and p16 pathway (Reznikoff et al. 1996a; Kiyono et al. 1998; Jarrard et al. 1999; Dickson et al. 2000). Some groups have reported that when cultured on fibroblast feeder layers, mammary epithelial cells (Herbert et al. 2002) and keratinocytes (Herbert et al. 2002; Fu et al. 2003) do not exhibit elevated p16 associated senescence. Others have reported that p16 is elevated and is associated with senescence in keratinocytes in both a serum‐free and the feeder layer system (Rheinwald et al. 2002). These differences highlight the importance of recognizing the influence of the culture system in which an investigation is performed. Different culture conditions are known to result in differential expression of p16 and hTERT, as well as different levels of telomerase activity in keratinocytes that were immortalized with human papillomavirus type 16 (HPV‐16) oncogenes E6 and/or E7 (Fu et al. 2003). E7 binds to the pRB (Dyson et al. 1989), which is known to play an important role in cell cycle control (Dyson 1998). pRB binds to and represses certain E2F transcription factors (Helin et al. 1993), which are involved in the transcriptional activation of many genes, including cell cycle control genes that enable G1‐S cell‐cycle progression (Dyson 1998). Thus, through interfering with pRB/E2F complex formation, E7 could override pRB‐mediated G1 cell cycle arrest. E6 binds to and induces the degradation of p53 (Scheffner et al. 1990), as well as inducing telomerase activity by activating transcription of the hTERT gene (Veldman et al. 2001). The exact mechanism of transcriptional activation is not fully known, and there is discrepancy in the literature regarding what is known about the mechanism. Some report an association between E6 and c‐Myc in activating hTERT transcription (McMurray & McCance 2003; Veldman et al. 2003), and others report activation of hTERT expression is not c‐Myc dependent (Gewin & Galloway 2001). Another hypothesis proposed is that a novel telomerase repressor, NFX‐91, is targeted for ubiquitination and degradation by E6‐E6AP complexes, resulting in the de‐repression of the hTERT promoter (Gewin et al. 2004).
Transformation with HPV‐16 E6 and/or E7 has been used for the immortalization of many types of epithelial cells (Halbert et al. 1991; Shay et al. 1993; Reznikoff et al. 1994, , 1996b; Foster & Galloway 1996; Kiyono et al. 1998; McMurray & McCance 2004), including urothelial cells (Reznikoff et al. 1994,, 1996a), and it has proven to be a very effective system. However, the studies in which urothelial cells have been immortalized using either HPV‐16 E6 or E6/E7 were performed in undefined cell culture systems that contained either bovine pituitary extract (Diggle et al. 2000, , 2001) or foetal bovine serum (FBS) (Reznikoff et al. 1994,, 1996a; Savelieva et al. 1997; Vieten et al. 1998), respectively. A recent study performed in a different culture system from ours and the HPV‐16 E6/E7 studies, has reported the immortalization of urothelial cells through retroviral expression of hTERT without the requirement for RB/p16 pathway alteration (Chapman et al. 2006). Due to previously reported differences in the HPV‐16 E6/E7 immortalization of keratinocytes that were attributed to cell culture conditions (Fu et al. 2003), we have sought to immortalize urothelial cells in a defined, serum‐free culture system via retroviral transformation with HPV‐16 E6 and E7 genes. Here we describe our success and provide characterization and comparison between parental untransformed cultures and immortalized cultures.
MATERIALS AND METHODS
Retroviral vector
The pLXSN16E6E7 vector containing the HPV‐16 E6 and E7 genes, under control of the Moloney murine leukaemia virus (MoMuLV) promoter‐enhancer sequences, confers resistance to the antibiotic neomycin (G418) (Halbert et al. 1991). This vector was obtained from the American Type Culture Collection already packaged in the mouse amphotropic packaging cell line PA317 – this cell line is termed PA317 LXSN 16E6E7. Viral supernatants were collected, filtered through 0.45 µm pore cellulose acetate, and were stored at −70 °C until use.
Cell culture
Ureteric or bladder tissue was obtained with informed consent under a human subjects’ protocol, approved by the Institutional Review Board of the Children's Hospital and Regional Medical Center. Tissue explants were processed in a protocol based on previously published methods (Bagai et al. 2002; Hudson et al. 2005; Delostrinos et al. 2006; Zhang et al. 2006). Surgical explant tissue was incubated in 0.1% ethylenediaminetetraacetic acid (EDTA) pH 8.0, 10 mm 4‐(2‐hydroxyethyl)‐1‐piperazineethane‐sulphonic acid (HEPES) (pH 7.2–7.5) in 1 mm phosphate‐buffered saline (1 × PBS) at 4 °C for 16–24 h. After washing twice with 1 × Hank's balanced salt solution (HBSS), tissue was minced, and then was washed three times more with 1 × HBSS. Minced tissue pieces were then incubated in 1 × HBSS, 10 mm HEPES (pH 7.4), 0.0055 mm CaCl2 and 200 U/ml type IV collagenase from Clostridium spp. (Sigma‐Aldrich, St. Louis, MO, USA) for 10 min at 37 °C. Following incubation, minced tissue was washed twice with warmed Dulbecco's Modified Eagle's Medium (DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (Invitrogen), separating the minced tissue into equal aliquots upon the second washing. The tissue aliquots were then re‐suspended into 3 ml of either non‐infectious DMEM or infectious DMEM containing HPV‐16 E6/E7 retrovirus. Cholera toxin and polybrene (Sigma) were added to final concentrations of 0.03 µg/ml and 4 µg/ml, respectively. The tissue re‐suspensions were plated into three 6‐well Primaria plates. After 24 h, all plating medium was replaced with a 50/50 (v/v) mixture of DMEM and Defined Keratinocyte Serum Free Medium supplemented with the manufacturer's growth supplement (DK‐SFM + GS) (Invitrogen). After 36 h, this medium was removed and cells were fed with the selection medium DK‐SFM + GS with 10 µg/ml G418 (Sigma). Selection was viewed as complete when the selection medium killed all cells in one of the non‐infected control wells. All transformed cells continued to be cultured in DK‐SFM + GS containing 10 µg/ml G418 after the selection period, and all untransformed cells were maintained in DK‐SFM + GS, unless otherwise noted.
Telomerase activity assay
Telomerase activity of cell culture samples was determined using the TRAPeze® Gel‐Based Telomerase Detection Kit (Chemicon, Temecula, CA, USA) (Feng et al. 1995). For the assay, cell pellets of 1 × 105 cells were collected, and were lysed in the supplied 1 × CHAPS lysis buffer with the addition of RNAsin Plus (Promega, Madison, WI, USA) 200 units/ml final concentration for 30 min on ice. Lysates were then sedimented at 12 000 × g for 20 min at 4 °C, and the cell extract supernatant was transferred to a clean tube. Protein concentrations were determined with the Pierce Bicinchoninic acid Protein Assay Kit and a Bio‐Tek PowerWave XS plate reader. All extracts were aliquoted and stored at −80 °C, and were thawed only for single use. Extracts were diluted to 0.5 µg/ml of total protein in 1 × CHAPS buffer (with RNAsin Plus) for the subsequent reactions.
Reaction mixtures contained 2 µl of test extract, AmpliTaq Gold DNA polymerase (Roche, Indianapolis, IN, USA), RNAsin, and the deoxyribonucleotide triphosphates, primers, and TRAP reaction buffer provided in the TRAPeze kit. Reactions were incubated at 30 °C for 30 min, then PCR amplified though 40 cycles of 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min in a PerkinElmer GeneAmp 2400 thermocycler (Perkin Elmer, Waltham, MA, USA). PCR products were electrophoresed in a 12.5% non‐denaturing polyacrylamide gel, stained with Sybr Green I (Molecular Probes, Eugene, OR, USA) and visualized with a Molecular Dynamics FluorImager SI (Sunnyvale, CA, USA).
Analysis of each sample included two assays: one reaction with test extract and one reaction with heat‐treated test extract. Heat‐treatment at 85 °C for 10 min inactivates telomerase because it is a heat‐sensitive enzyme. Heat‐treated samples served as negative controls. In addition to the positive control and primer‐dimer/PCR contamination controls provided by the kit, cell extracts were generated from the UM‐UC‐3 transitional cell carcinoma cell line to use as an additional positive control (Grossman et al. 1986). These cells were cultured in Eagles’ minimum essential medium supplemented with 2 mm l‐glutamine, Earle's balanced salt solution adjusted to contain 1.5 g/l sodium bicarbonate, 0.1 mm non‐essential amino acids, 1 mm sodium pyruvate and 10% FBS.
Growth curves
Cells were seeded at a density of 1.67–2.53 × 105 cells per 25 cm2 flask in DK‐SFM. When individual flasks approached 90% confluency, cells were harvested with trypsin and were counted using a haemocytometer. A fraction of counted cells was re‐plated – this process was repeated for 30 days. All cells were accounted for in generating growth curves. Exponential trend lines, along with corresponding exponential equations and correlation coefficients, were generated with Microsoft Excel. Doubling times were calculated by solving for x at two y‐values that differed by a factor of 2. Collection data for the growth curve was performed between passages 3 and 8, from day 19 to day 48 in culture for non‐transformed cells, and between passages 53 and 58, from day 238 to day 263 in culture for transformed cells.
DNA synthesis assays
For the purposes of this assay, DK‐SFM was used both with (DK‐SFM + GS) or without (DK‐SFM − GS) the manufacturer's growth factor supplement (GS). Untransformed and transformed urothelial cell cultures were grown in 96‐well tissue culture plates (Costar, Corning, NY, USA) in DK‐SFM + GS. At 80% confluency, cultures were washed twice with DK‐SFM‐GS and fed DK‐SFM that contained 5 µg/ml heparin (Sigma), with or without GS, and with or without 1 µm PD‐153035 (Roche), a potent epidermal growth factor receptor (EGFR) inhibitor. PD‐153035 blocks autophosphorylation of EGFR, preventing any downstream signalling from this receptor (Fry et al. 1994). Cells were incubated under these conditions for 45 h, after which 5‐bromo‐2′‐doexyuridine (BrdU; Roche) was added to all wells to a 10‐µm final concentration. After 2 h exposure to BrdU, cells were fixed for 0.5 h and were incubated for 1.5 h with a monoclonal mouse anti‐BrdU antibody conjugated to horseradish peroxidase (Cell Proliferation ELISA, BrdU, Roche). Addition of tetramethyl‐benzidine to each well produced a colorimetric reaction between the peroxidase and this substrate, and relative DNA synthesis was correlated with absorbance at 370 nm in each well.
Immunocytochemistry
Transformed and untransformed urothelial cells were screened for immunoreactivity with anti‐cytokeratin antibodies (Table 1). Cells seeded onto coverslips were grown to 70% confluence, then were fixed with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) in PBS (pH 7.4) (Sigma) for 15 min at room temperature. Following fixation, coverslips were washed three times, for 5 min each, with 0.01 m PBS (pH 7.4), 0.05% Tween 20 (Sigma) (PBS‐T). Coversliped cells were then blocked with 5% normal goat serum (Vector Laboratories, Burlingame, CA, USA) in PBS (pH 7.4) for 30 min at room temperature, and were rinsed briefly with PBS‐T. Twelve to sixteen hours of incubation with a mouse monoclonal primary antibody was performed at 4 °C, followed by three 5‐min washes with PBS‐T. Cells were then incubated with 7.5 µg/ml goat anti‐mouse immunoglobulin G conjugated with Cy2 fluor (Jackson Immuno Research, West Grove, PA, USA) for 1 h at room temperature, and were washed three times, for 5 min each, with PBS‐T. Coverslips were then washed twice for 5 min each with reverse osmosis deionized water, then cells were stained with 4′,6‐diamidino‐2‐phenylindole (DAPI) (Molecular Probes) for 2 min at room temperature. Three 5‐min washes with PBS‐T were performed following DAPI staining, and coverslips were mounted with ProLong Antifade Mounting Media (Molecular Probes). Negative controls consisted of omitting the primary antibody step. Auto‐fluorescence controls consisted of fixing and mounting cells with no further processing performed. Cells were viewed using a Leica DMI 6000B inverted fluorescence microscope with a Leica 40× correction collar objective. Images of 1300 × 1030 resolution were captured using a Leica DC 500 CCD digital camera.
Table 1.
Cytokeratin expression in parental and immortalized cultures
| Antibody | Source | Location | Species | Concentration used | Parental line | Immortal line |
|---|---|---|---|---|---|---|
| CK 7 | Novocastra | Newcastle Upon Tyne, UK | mouse | 1 µg/ml | + | + |
| CK 8 | Zymed | San Francisco, CA, USA | mouse | 2.1 µg/ml | + | + |
| CK 10 | Chemicon | Temecula, CA, USA | mouse | 1 : 200 dilution of ascites fluid | + | + |
| CK 13 | Abcam | Cambridge, MA, USA | mouse | 1 : 100 dilution of tissue culture supernatant | – | – |
| CK 14 | Serotec | Oxford, UK | mouse | 5 µg/ml | + | + |
| CK 17 | Sigma | St. Louis, MO, USA | mouse | 8.5 µg/ml | + | + |
| CK 18 | Sigma | St. Louis, MO, USA | mouse | 5.5 µg/ml | + | + |
| CK 19 | Novocastra | Newcastle Upon Tyne, UK | mouse | 1 : 100 dilution of tissue culture supernatant | + | + |
| CK 20 | Fitzgerald | Concord, MA, USA | mouse | 1 µg/ml | – | – |
Cytogenetic analysis
Metaphase chromosome spreads from cultures of untransformed urothelial cells at passage 4 and from transformed cells at passages 3, 21 and 54 were harvested and G‐banded (Wright's stain) using standard cytogenetic techniques (Priest 1997). Briefly, the culture medium was removed and cells were incubated with 0.06 µg/µl of colcemid (Invitrogen) at 37 °C for 2.5 h. They were then detached from the T‐25 flasks with trypsin/EDTA (0.5%/0.1%) and were incubated in 10 ml of 1 : 1 (v/v) mixture of 0.8% sodium citrate and 0.075 m potassium chloride for 30 min at 37 °C. This was followed by the slow addition of 5 ml Carnoy's fixative (3 : 1 (v/v); methanol : acetic acid). Cells were centrifuged 10 min at 200 × g, then were re‐suspended in 10 ml Carnoy's fixative, and were incubated at room temperature for 30 min. Following fixation, the cells were centrifuged and were re‐suspended in 10 ml of Carnoy's fixative twice more. For analysis, suspensions of fixed nuclei were applied dropwise to a moistened microscope slide to yield metaphase spreads, which were treated with trypsin, followed by Wright's stain to give G‐banded chromosomes. Cell parameters were analysed using a digital imaging system (Applied Imaging, Santa Clara, CA, USA), and karyotypes were described according to the recommendations of the International System for Human Cytogenetic Nomenclature (Shaffer & Tommerup 2005).
Single‐cell sorting of transformed cells
Transformed cells at passage 49 were incubated in Versene (Invitrogen) at 37 °C for 5 min until the cells rounded up. These were then incubated in 0.25% (v/v) trypsin (Invitrogen) in Versene until they detached. Cells were pelleted by sedimentation at 180 × g for 5 min, then were washed once with DK‐SFM. The final cell pellet was re‐suspended in 1 ml of DK‐SFM, and 1 ml of Accumax (Innovative Cell Technologies Inc., San Diego, CA, USA) was added to the cell suspension. The suspension was incubated for 10 min at 37 °C to disperse cell clumps. Cells were then single sorted into 96‐well Primaria™ plates using an Influx flow cytometer cell sorter located in the Department of Pathology at the University of Washington, Seattle, WA, USA.
RESULTS
Results described in this section were obtained from work performed on two ureter cell lines and one bladder cell line. Unless otherwise mentioned, urothelial cells described in this section refer to the ureter cell lines.
Telomerase activity in parental, untransformed cells
Untransformed human urothelial cell lines were tested for telomerase activity by the TRAP assay. Cultures with telomerase activity add telomeric repeats on to the 3′ end of an oligonucleotide substrate. Subsequent PCR amplification of these extension products generated a ladder that increased by 6 bp starting at 50 bp. A 36‐bp internal standard product was also generated in each reaction. This internal control band indicated some PCR inhibition present in telomerase positive samples; however, PCR inhibition was minimal in telomerase negative samples. All telomerase activity levels observed in untransformed urothelial cell cultures were lower than activity levels in the UM‐UC‐3 transitional cell carcinoma (TCC) line tested (Fig. 1, lanes 2 and 3). This TCC line was used as a positive control as it has been documented that TCC, like many tumour cells, exhibit high levels of telomerase activity (Belair et al. 1997; Kinoshita et al. 1997). Both ureter and bladder cell cultures exhibited low levels of telomerase activity (Fig. 1, lanes 4 and 10, respectively). This finding supports previous reports of telomerase activity in cultured human urothelial cells (Belair et al. 1997; Puthenveettil et al. 1999). In our assays, telomerase activity level diminished rapidly with time in culture. A steady reduction of extension products is observed in a cell culture with continued passage (Fig. 1, lanes 4, 6 and 8). For comparison, a bladder cell culture is shown at passage 4, 33 days total, which exhibits extremely low activity (Fig. 1, lane 10). In a ureter cell culture, at passage 6, 60 days total, telomerase activity was almost undetectable (Fig. 2, lane 4).
Figure 1.

Telomerase activity levels in untransformed cells as detected by TRAP assay. Shown is a 12.5% polyacrylamide gel stained with Sybr Green I. 1: molecular weight marker bp. 3, 5, 7, 9 and 11: heat inactivated samples. 2 and 3: UM‐UC‐3 transitional bladder carcinoma. 4 and 5: ureter cells, P4, 19 days in culture. 6 and 7: ureter cells, P5, 23 days in culture. 8 and 9: ureter cells P6, 28 days in culture. 10 and 11: bladder cells, P4, 33 days in culture.
Figure 2.

Restoration of telomerase activity by transformation with HVP‐16 E6/E7 detected by TRAP assay. Shown is a composite 12.5% polyacrylamide gel stained with Sybr Green I. 1: molecular weight marker bp. 3, 5 and 7: heat inactivated samples. 2 and 3: UM‐UC‐3 transitional bladder carcinoma cell line. 4 and 5: normal, untransformed cells at passage 6, 60 days in culture. 6 and 7: cells transformed with E6/E7, passage 4, 27 days in culture.
Transformation of normal human urothelial cultures
Transformation with HPV‐16 E6/E7 at initial plating produced foci of rapidly multiplying cells. During the selection period, 60–70% of cells succumbed to antibiotic treatment, while 30–40% remained healthy and continued to proliferate under selection conditions, yielding a culture of transformed cells with extended lifespan.
Immortalization results in restoration of telomerase activity
Urothelial cell cultures transformed with HPV‐16 E6/E7 exhibited strong telomerase activity (Fig. 2). Untransformed cells after as little as 28 days in culture showed very little telomerase activity (Fig. 1, lanes 8 and 10), while transformed cells at 27 and 47 days in culture showed much higher telomerase activity levels in comparison (Fig. 2, lane 6). TRAP assays performed on transformed cells generated DNA ladders with as many as nine clearly visible extension products (Fig. 2, lane 6), which was an activity level similar to that of the transitional cell carcinoma positive control (Fig. 2, lane 2).
Retention of cellular phenotype in immortalized urothelial cultures
Cultures of transformed and non‐transformed cells passaged at equivalent densities, exhibited highly similar attachment and spreading kinetics (not shown) and displayed cobblestone morphology typified by ‘giant’ cells surrounded by smaller basal cells (Fig. 3a,b,e–h). After 40–60 doublings, untransformed cells between passages 4–10 exhibited the following characteristics of senescence: increased blebbing, larger cytoplasmic areas, decreased cobblestone appearance, and had a larger, more flattened appearance (Fig. 3c,d). In contrast, HPV‐16 E6/E7‐transformed urothelial cells had not exhibited senescent morphological characteristics at 641 days in culture. Transformed cells at passages 10, 29 and 59 (73, 139 and 266 days in culture, respectively) (Fig. 3f–h), exhibited morphology almost identical to healthy, early passage, non‐transformed cells (Fig. 3a,b). At the time of submission of this manuscript, the transformed cell mass culture had reached passage 127, which is 641 days in culture.
Figure 3.

Urothelial cells transformed with HPV‐16 E6E7 exhibit a normal morphology by phase contrast microscopy. (a–d) Untransformed cells. (e–f) Transformed cells. (a) Ureter cells, P2, 17 days in culture. (b) Ureter cells, P4, 31 days in culture. (c) Ureter cells, P10, 73 days in culture. (d) Bladder cells, P4, 46 days in culture. (e) Ureter cells, P4, 31 days in culture. (f) Ureter cells, P10, 73 days in culture. (g) Ureter cells, P29, 139 days in culture. (h) Ureter cells, P59, 266 days in culture. 10× magnification; size bar is 40 µm.
Growth rates of transformed and untransformed cultures
A growth curve was constructed of the untransformed and transformed cultures over a 30‐day period (Fig. 4). For the first 15–17 days, both types of cell culture exhibited similar growth, with doubling times roughly constant over the first 20 days. Beginning at day 20, untransformed cell culture growth slowed with increased passage number and time in culture (Fig. 4). Doubling times were calculated as 57 h for the untransformed cells, and 37 h for the transformed cells, over the same time period. Our data and some comparative examples are provided in Table 2.
Figure 4.

Growth curve of untransformed and transformed urothelial cells. (a) Log scale. (b) Non‐log scale. Cells were seeded into a T75 cm2 flask in DK‐SFM, harvested at 90% confluency and counted. All cells were accounted for in calculations. Time 0 represents passage 3, day 19 in culture for untransformed cells, and passage 53, day 238 in culture for transformed cells.
Table 2.
Comparison of doubling time amongst various epithelial cell lines
| Cell line | Time of 1 cell cycle | Medium used 1 | Reference |
|---|---|---|---|
| Parental flask 1 – normal urothelial | 52 h | DK‐SFM, defined, serum‐free, with epidermal growth factor (EGF) and proprietary growth supplement | Data from Fig. 3 |
| Parental flask 2 – normal urothelial | 52 h | DK‐SFM, defined, serum‐free, with EGF and proprietary growth supplement | Data from Fig. 3 |
| Transformed flask 1 – normal urothelial | 37 h | DK‐SFM, defined, serum‐free, with EGF and proprietary growth supplement | Data from Fig. 3 |
| Transformed flask 2 – normal urothelial | 37 h | DK‐SFM, defined, serum‐free, with EGF and proprietary growth supplement | Data from Fig. 3 |
| Normal human urothelial primary cultures | 14.7 h | K‐SFM, undefined, serum‐free, with EGF and bovine pituitary extract | Southgate et al. 1994; Delostrinos et al. 2006 |
| Normal human urothelial primary cultures | 51 h | HMRI‐1, undefined, serum‐free, with EGF and bovine pituitary extract | Kirk et al. 1985 |
| Foetal oral epithelial line | 90, 55 and 26.5 h for different lines | DK‐SFM, defined, serum‐free, with EGF and proprietary growth supplement | Gilchrist et al. 2000 |
| Conjunctiva epithelial line | 16.5 h | DMEM, with 10% serum | Girjes et al. 2003 |
| Conjunctiva epithelial line | 26.5 h | DMEM, with 2% serum | Girjes et al. 2003 |
DK‐SFM, defined keratinocyte‐serum free medium; K‐SFM, keratinocyte‐serum free medium; HMRI‐1, modified MCDB 153 medium; DMEM, Dulbecco's modified Eagle medium.
Control of EGF‐dependent cell‐cycle progression in parental and immortalized cultures
Based on the reduced doubling times of immortalized cell cultures, we decided to investigate the extent to which untransformed and transformed cell cultures could be rendered quiescent. BrdU assays were performed to quantify DNA synthesis after subjecting both the transformed and untransformed cells to varying growth conditions. Cells were grown in DK‐SFM either with or without GSs, and either with or without PD‐153035. DNA synthesis in untransformed and transformed cultures grown in DK‐SFM with GSs and without PD‐153035 is shown in Fig. 5 (a and b, respectively, bars with horizontal lines). These bars represent normal growth. Removal of GSs caused a 61% reduction of DNA synthesis in the untransformed cells (Fig. 5a, grid bar) and a 45% reduction in the transformed cells (Fig. 5b, grid bar). Addition of PD‐153035 to a final concentration of 1 µm resulted in a 10% reduction in DNA synthesis in untransformed cells (Fig. 5a, grey bar) and 45% reduction of DNA synthesis in the transformed cells (Fig. 5b, grey bar). When cells were subjected to removal of GSs in addition to EGFR pathway inhibition with PD‐153035, the level of DNA synthesis in untransformed cells was reduced by 99% (Fig. 5a, black bar) and in transformed cells by 93% (Fig. 5b, black bar).
Figure 5.

Removal of growth supplements (GS) and addition of EGFR inhibitor PD‐153035 renders transformed and untransformed cultures quiescent. Cultures were fed DK‐SFM with or without growth supplements and with or without EGFR inhibitor as previously described in the Materials and methods. The absorbance at 370 nm represents BrdU incorporation into cellular DNA. For each condition, n = 8, and error bars represent SEM. (a) Parental, untransformed cells. (b) Immortalized cells.
Cytokeratin expression
By immunocytochemistry, untransformed and transformed cells were screened for differences in cytokeratin expression. Cytokeratin expression is a marker of differentiation in urothelial cells (Moll et al. 1988). A complete list of the cytokeratins tested, along with the results, can be found in Table 1. Both untransformed and transformed urothelial cells were immunoreactive with antibodies raised against cytokeratins 7, 8, 10, 14, 17, 18 and 19 and nonimmunoreactive for cytokeratins 13 and 20. There were no differences in the staining patterns between the transformed and untransformed cells, as exemplified by staining for cytokeratins 7, 14 and 17 shown in Fig. 6.
Figure 6.

Retention of cytokeratins 7, 14 and 17 expression by immortalized cells shown by immunocytochemistry. (a–c) Normal untransformed ureter cells, passage 4, 31 days in culture. (d–f) Ureter cells transformed with E6E7, passage 4, 31 days in culture. (a, d) Cytokeratin 7. (b, e) Cytokeratin 14. (c, f) Cytokeratin 17. 40× magnification; size bar is 20 µm.
Karyotypes of parental and immortalized cells
To assess the extent that immortalization induced chromosomal rearrangement, cytogenetic analysis of metaphase spreads by G‐banding was performed (Table 3). Figure 7 describes data collection for parallel untransformed and transformed cell cultures. The number of metaphase cells available was limited, and only five metaphase cells were scored for each culture analysed. Untransformed parental cells at passage 4 (23 days in culture) yielded a normal 46, XY karyotype. Transformed cells at passage 3 (27 days in culture) also yielded a normal 46, XY karyotype. Upon analysis of passage 21 (101 days in culture) transformed cells, four, related, abnormal karyotypes were detected. All five of these metaphases had at least one extra copy of chromosome 20. In two cells (by definition a clonal abnormality) this was the sole abnormality and in the other three cells aneuploidy was present. More complex karyotypes, indicating evolution of the previously abnormal cells, were detected in passage 54 (241 days in culture). Again, all five of these metaphases had at least one extra copy of chromosome 20, and in addition to aneuploidy for several chromosomes, a structural rearrangement, an apparently balanced translocation between the long arm of a chromosome 9 and the long arm of a chromosome 15, was present in three cells (again, by definition a clonal abnormality).
Table 3.
Karyotypes of transformed and untransformed urothelial cells
| Cells | Karyotype |
|---|---|
| Parental, passage 4, 23 days in culture | 46, XY [5] a |
| Transformed, passage 3, 27 days in culture | 46, XY [5] |
| Transformed, passage 21, 101 days in culture | 47, XY, +20 [2] |
| 48, XY, +6, +20 [1] | |
| 49, XY, +6, +20, +20 [1] | |
| 50, X, –Y, +5, +9, +9, +20, +20 [1] | |
| Transformed, passage 54, 241 days in culture | 52, XY, +5, +6, +7, +9, t(9; 15)(q34; q22), +20, +20 [3] |
| 51, XY, +5, +6, +7, +9, −13, +der(15)t(9; 15)(q34; q22), +20 [1] | |
| 51, XY, +5, +6, +7, +9, +20 [1] |
number of cells with this karyotype are indicated in brackets.
Figure 7.

Time line of cell culture growth.‘Parental’ refers to the untransformed culture. ‘Immortalized’ refers to the parallel culture transformed with HPV‐16 E6E7. Both cultures originated from the same surgical explant.
Generation of single cell clones from immortalized cell cultures
Passage 49 cells were trypsinized and were single cell sorted into each of 96‐well plates. Only 18/96 wells seeded survived and grew into colonies that could be further passaged from the 96‐well plate into a 48‐well plate. With each passage, the size of the tissue culture wells was steadily increased until the single cell clones were in T25 flasks at passage 55. Of the initial 18 colonies that survived, only 14 survived to passage 55, and the length of time it took for the colonies to arrive at that passage number varied from 36 days post‐sorting to 62 days post‐sorting. All single cell‐derived clones exhibited cell morphology similar to both mass transformed cell cultures and parental cultures. The clones remain cryopreserved for characterization at a later date.
Telomerase activity in single cell‐sorted clones
After single cell‐derived clones were established, three different clones were assayed for telomerase activity at passage 57 (266 days in culture). While all three clones exhibited telomerase activity, the level of activity varied between them (Fig. 8, lanes 2, 4 and 6). The clone with the highest telomerase activity level generated a DNA ladder with six easily detectable extension products (Fig. 8, lane 2) similar to the level exhibited by the mass transformed culture assayed at passage 59 (266 days in culture) (Fig. 8, lane 10). The other two clones exhibited lower levels of activity: one clone with a DNA ladder of only three distinct bands and three faint bands (Fig. 8, lane 6), and one clone that generated a ladder with only two clearly visible bands and two very faint bands (Fig. 8, lane 4). The weakest telomerase activity level present in the clones was still greater than the activity level detected in untransformed parental cells assayed at passage 6 (60 days in culture) (Fig. 8, lane 8).
Figure 8.

Restoration of telomerase activity to single cell clones detected by TRAP assay. Shown are two 12.5% polyacrylamide gels stained with Sybr Green I. 1: molecular weight marker bp. 3, 5, 7, 9 and 11: heat inactivated samples. 2, 4 and 6: telomerase activity level in 3 different single cell clones at P57, 266 days in culture. 8: normal untransformed culture, passage 6, 60 days in culture. 10: transformed mass culture, passage 59, 266 days in culture. All single cell clones were sorted from the mass culture at passage 50.
DISCUSSION
Telomerase activity has been detected in a high percentage of malignant tumours, including in 98% of bladder cancers, and it has been shown that both TCC biopsies and TCC in vitro cell cultures exhibit telomerase activity (Belair et al. 1997). Interestingly, it has been reported that in vitro cultures of urothelial cells exhibited telomerase activity that diminished with continued passage, while telomerase activity was not detected in uncultured specimens of normal urothelial cells (Belair et al. 1997). However, there are reports of low level telomerase activity in tissues that are self‐renewing (Forsythe et al. 2002), and reports of the detection of telomerase expression in some epithelial cells and lymphocytes while proliferating in vivo (Holt et al. 1997). In addition, it has been reported that some types of telomerase‐positive cells become telomerase‐negative when arrested in G0, and that this down‐regulation of telomerase activity is reversible when cells re‐enter the cell cycle and begin proliferation (Holt et al. 1996). Taken together, these reports have led to the hypothesis that telomerase activity is more closely associated with cell proliferation, rather than with malignant transformation (Belair et al. 1997; Holt et al. 1997). As urothelial cells in vitro adopt a highly proliferative phenotype (Southgate et al. 1994), it is not unexpected that telomerase activity might be detected in earlier passage cultures. In agreement with previous findings (Belair et al. 1997), our early passage untransformed urothelial cells exhibited telomerase activity that was markedly reduced to almost undetectable levels with continued passage of the cultures. In contrast, urothelial cells transformed with HPV‐16 E6/E7, did not exhibit a reduction in telomerase activity with continued passage. Transformation with HPV‐16 E6/E7 yielded not only the restoration of telomerase activity, but also an increase in telomerase activity to nearly the levels exhibited by the UM‐UC‐3 TCC cell line.
It has been shown that culture conditions can alter the doubling times for urothelial cells grown in vitro. Factors that have been shown to influence this are calcium concentration, growth factor supplementation and serum supplementation, although there is some discrepancy within the literature regarding which conditions are more favourable for cell proliferation. This is most likely due to the studies investigating the effects of these factors being carried out in different culture media systems. The literature lists doubling times ranging from 24 h to 77 h (Kirk et al. 1985; Reznikoff et al. 1986; Dubeau & Jones 1987; Petzoldt et al. 1994). In this study, doubling time for untransformed cells fell in the middle of this range, at 52 h, while the transformed cells exhibited a doubling time of 37 h. The overall slower doubling time for untransformed cells could be attributed to the inclusion of days 20–27 in the growth curve. Beginning at day 20, untransformed cells had started to exhibit morphology consistent with senescence and did not maintain the growth rate of transformed cells.
While difference in doubling times could be attributed to the beginning of senescence in untransformed cells, we decided to also confirm that transformed cells had not acquired a phenotype characterized by uncontrollable growth. The removal of GSs from the culture medium reduced DNA synthesis in untransformed and transformed cultures alike, although untransformed cultures showed 16% greater reduction than the transformed cells. The combination of GS removal and EGF pathway inhibition rendered both the untransformed and transformed cultures nearly quiescent. This suggests the mechanisms by which the HPV‐16 E6 and E7 genes immortalize urothelial cells do not confer uncontrollable cell‐cycle progression. The signals required for continued cell cycling in vitro have not been ‘overridden’ or negated. The minor DNA synthesis that remained may be due to residual growth factors still bound to cells, incomplete inhibition of the EGF pathway by PD‐153035 or transforming growth factor‐α (TGF‐α).
Both transformed and untransformed cell cultures exhibited the same cytokeratin expression profiles, indicating that the immortalized cells were not exhibiting uncharacteristic differentiation. In agreement with previous findings for normal human urothelial cells (Southgate et al. 1994), both the transformed and non‐transformed cells were immunoreactive for CKs 7, 8, 14, 17, 18 and 19, while testing negative for CKs 13 and 20. A CK 16 immunoglobulin G was not used. Immortalized cells exhibited previously reported markers of transitional (Moll et al. 1988; Southgate et al. 1994) and of squamous (Southgate et al. 1994; Harnden & Southgate 1997) epithelia, suggesting that an immature phenotype resulted as a consequence of reversal of differentiation. While complete loss of CK 13 expression has not been previously reported, it has been shown that in serum‐free growth conditions urothelial cultures switch to a more squamous phenotype evidenced by the reduced CK 13 expression and increased CK 14 expression (Cross et al. 2005).
Genetic alterations seen in our immortalized cells were not unexpected. A variety of genetic alterations has been reported in human urothelial cells immortalized with either HVP‐16 E6 and/or E7 genes (1994, 1996b; Savelieva et al. 1997; Vieten et al. 1998; Cuthill et al. 1999). It has been shown that urothelial cells immortalized with HPV‐16 E6 or E7, have exhibited combinations of clonal losses of chromosome regions 3p, 6q, 9p, 11p, 18q and Y, and gains of chromosome regions 3q, 7, 9q and 20q (1996a, 1996b). Some studies have suggested a 20q gain as an event associated with immortalization of urothelial cells after transformation with HPV‐16 E7 (Savelieva et al. 1997; Cuthill et al. 1999). It is noteworthy that gain of at least one copy of chromosome 20 was seen in every abnormal cell. An association between chromosome 3 deletion and the immortalization of urothelial cells by transformation with HPV‐16 E6 has been described, but chromosome 3 deletion in HPV‐16 E7 transformed urothelial cells has also been observed (Vieten et al. 1998). The significance of other genetic alterations in relationship to the immortalization of urothelial cells is not fully known, although some of the alterations have been studied within the context of malignant transformation. It is thought that loss of a chromosome indicates the possibility of that chromosome containing tumour suppressor gene(s), and gain of a chromosome indicates the possibility that the chromosome may contain oncogene(s) (Reznikoff et al. 1996b). We recognize that the karyotypic alterations seen in immortalized cell lines are likely to alter or compromise some functions within the cell. While this is indeed a potential shortcoming for investigations aimed at elucidating specific mechanisms or pathways in normal cells, immortalized cell lines can still provide a useful tool for the investigation of diseases in which altered karyotypes are observed, such as cancer. For our purposes, our data indicate that the genetic variance in our transformed cells does not alter their phenotype. In addition, the genetic variance neither inhibited culture propagation, nor conferred uncontrollable cell‐cycle progression.
After establishing transformed cultures, we performed multiple cell‐sorting experiments in an attempt to obtain homogeneous cultures, each derived from a single cell. Although we finally did obtain such cultures, it was not without great difficulty. The low success rate experienced during the single cell‐sorting process was not surprising. It has been reported that establishment of primary cultures requires a relatively high initial plating density (Southgate et al. 1994), and we routinely seed primary cultures at a plating density of 1 × 104 cells/cm2. While plating density requirements can be as low as 2.5 × 102 cells/cm2 when sub‐culturing established cell lines (Southgate et al. 1994), this density is equivalent to 80 cells in one well of a 96‐well plate. Being alone in a well is extremely stressful for a cell, in part due to minimal opportunity for growth signals from the autocrine loop involving epidermal growth factor receptor (EGFR) and heparin‐binding EGF‐like growth factor (HB‐EGF) (Varley et al. 2005). In addition, it has been reported that cell density has an effect on the expression of cell adhesion molecules that are involved in cell–cell and cell–matrix interactions (Stanley et al. 1995). If this is the case for urothelial cells, lower cell density could result in reduced expression of integrins that are important for cell adhesion and mobility, affecting cell proliferation.
While not presented in this report, we have been successful in extending the lifespan of several bladder urothelial cell cultures up to 30 passages before cryogenically storing them. It is therefore apparent that urothelial cells derived from embryonic endoderm (ureter) and embryonic mesoderm (bladder) are not refractory to immortalization by our methods.
While the HPV‐16 E6 and E7 immortalization of urothelial cells has previously been reported, the culture system used in those studies was an undefined system containing FBS (Reznikoff et al. 1994, , 1996a). In the present study, we have demonstrated that transformation of urothelial cells with HPV‐16 E6 and E7 genes in a defined, serum‐free culture system results in the restoration of telomerase activity and the immortalization of the transformed cell cultures. In our experiments, retroviral expression of hTERT alone did not confer an extended lifespan on urothelial cells. This is consistent with work published reporting the necessity for RB/p16 pathway alteration or inactivation for the immortalization of some epithelial cells (Reznikoff et al. 1996a; Kiyono et al. 1998; Jarrard et al. 1999; Dickson et al. 2000). However, a recent study reported that retroviral expression of hTERT resulted in the immortalization of urothelial cells without the inactivation of the RB/p16 pathway (Chapman et al. 2006). While this may seem contradictory, a direct comparison cannot be made due to key differences – different retroviral systems, different retroviral expression vectors and different culture systems were used. Of these three variables, the most interesting difference is cell culture system. We have employed a defined serum‐free culture system, while the contrasting study used an undefined serum‐free system containing bovine pituitary extract. As cell culture systems have been shown to influence the results of in vitro cell senescence studies, it must be considered that cultures systems could influence the immortalization of cells as well. The discrepancies within the current literature regarding urothelial cell senescence and immortalization bolster the need for continued efforts in developing a defined and reproducible system for urothelial cell immortalization.
ACKNOWLEDGEMENTS
We thank Dr. Richard Grady for providing surgical explant tissue, and Ms. Kirsten Beck for preparing karyotypes. This work was supported by NIDDK R01DK58881, NIDDK R01DK62251 (J.A.B.) and NIDDK 3U01‐DK065202‐01S1 (J.A.B.).
REFERENCES
- Bagai S, Rubio E, Cheng JF, Sweet R, Thomas R, Fuchs E, Grady R, Mitchell M, Bassuk JA (2002) Fibroblast growth factor‐10 is a mitogen for urothelial cells. J. Biol. Chem. 277, 23828–23837. [DOI] [PubMed] [Google Scholar]
- Belair CD, Yeager TR, Lopez PM, Reznikoff CA (1997) Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc. Natl. Acad. Sci. USA 94, 13677–13682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE (1998) Extension of lifespan by introduction of telomerase into normal human cells. Science 279, 349–352. [DOI] [PubMed] [Google Scholar]
- Brenner AJ, Stampfer MR, Aldaz CM (1998) Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 17, 199–205. [DOI] [PubMed] [Google Scholar]
- Chapman EJ, Hurst CD, Pitt E, Chambers P, Aveyard JS, Knowles MA (2006) Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene 25, 5037–5045. [DOI] [PubMed] [Google Scholar]
- Cross WR, Eardley I, Leese HJ, Southgate J (2005) A biomimetic tissue from cultured normal human urothelial cells: analysis of physiological function. Am. J. Physiol. Renal Physiol. 289, F459–F468. [DOI] [PubMed] [Google Scholar]
- Cuthill S, Agarwal P, Sarkar S, Savelieva E, Reznikoff CA (1999) Dominant genetic alterations in immortalization: role for 20q gain. Genes Chromosomes Cancer 26, 304–311. [PubMed] [Google Scholar]
- Delostrinos CF, Hudson AE, Feng WC, Kosman J, Bassuk JA (2006) The C‐terminal Ca2+‐binding domain of SPARC confers anti‐spreading activity to human urothelial cells. J. Cell. Physiol. 206, 211–220. [DOI] [PubMed] [Google Scholar]
- Di Donna S, Mamchaoui K, Cooper RN, Seigneurin‐Venin S, Tremblay J, Butler‐Browne GS, Mouly V (2003) Telomerase can extend the proliferative capacity of human myoblasts, but does not lead to their immortalization. Mol. Cancer Res. 1, 643–653. [PubMed] [Google Scholar]
- Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG (2000) Human keratinocytes that express hTERT and also bypass a p16 (INK4a)‐enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol. Cell. Biol. 20, 1436–1447. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Diggle CP, Pitt E, Harnden P, Trejdosiewicz LK, Southgate J (2001) Role of p53 in the responses of human urothelial cells to genotoxic damage. Int. J. Cancer 93, 199–203. [DOI] [PubMed] [Google Scholar]
- Diggle CP, Pitt E, Roberts P, Trejdosiewicz LK, Southgate J (2000) N;‐3 and n;‐6 polyunsaturated fatty acids induce cytostasis in human urothelial cells independent of p53 gene function. J. Lipid Res. 41, 1509–1515. [PubMed] [Google Scholar]
- Dubeau L, Jones PA (1987) Growth of normal and neoplastic urothelium and response to epidermal growth factor in a defined serum‐free medium. Cancer Res. 47, 2107–2112. [PubMed] [Google Scholar]
- Dyson N (1998) The regulation of E2F by pRB‐family proteins. Genes Dev. 12, 2245–2262. [DOI] [PubMed] [Google Scholar]
- Dyson N, Howley PM, Munger K, Harlow E (1989) The human papilloma virus‐16, E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934–937. [DOI] [PubMed] [Google Scholar]
- Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J (1995) The RNA component of human telomerase. Science 269, 1236–1241. [DOI] [PubMed] [Google Scholar]
- Forsythe HL, Elmore LW, Jensen KO, Landon MR, Holt SE (2002) Retroviral‐mediated expression of telomerase in normal human cells provides a selective growth advantage. Int. J. Oncol. 20, 1137–1143. [PubMed] [Google Scholar]
- Foster SA, Galloway DA (1996) Human papillomavirus type 16, E7 alleviates a proliferation block in early passage human mammary epithelial cells. Oncogene 12, 1773–1779. [PubMed] [Google Scholar]
- Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ (1994) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 265, 1093–1095. [DOI] [PubMed] [Google Scholar]
- Fu B, Quintero J, Baker CC (2003) Keratinocyte growth conditions modulate telomerase expression, senescence, and immortalization by human papillomavirus type 16, E6 and E7 oncogenes. Cancer Res. 63, 7815–7824. [PubMed] [Google Scholar]
- Gewin L, Galloway DA (2001) E box‐dependent activation of telomerase by human papillomavirus type 16, E6 does not require induction of c‐myc. J. Virol. 75, 7198–7201. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gewin L, Myers H, Kiyono T, Galloway DA (2004) Identification of a novel telomerase repressor that interacts with the human papillomavirus type‐16, E6/E6‐AP complex. Genes Dev. 18, 2269–2282. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gilchrist EP, Moyer MP, Shillitoe EJ, Clare N, Murrah VA (2000) Establishment of a human polyclonal oral epithelial cell line. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 90, 340–347. [DOI] [PubMed] [Google Scholar]
- Girjes AA, Lee KE, Carrick FN (2003) Establishment and characterization of a new epithelial cell line, KC‐1, from koala (Phascolarctos cinereus) conjunctiva. In Vitro Cell. Dev. Biol. Anim. 39, 110–113. [DOI] [PubMed] [Google Scholar]
- Grossman HB, Wedemeyer G, Ren L, Wilson GN, Cox B (1986) Improved growth of human urothelial carcinoma cell cultures. J. Urol. 136, 953–959. [DOI] [PubMed] [Google Scholar]
- Halbert CL, Demers GW, Galloway DA (1991) The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65, 473–478. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Harley CB, Futcher AB, Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345, 458–460. [DOI] [PubMed] [Google Scholar]
- Harnden P, Southgate J (1997) Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas. J. Clin. Pathol. 50, 1032–1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hayflick L, Moorhead PS (1961) The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621. [DOI] [PubMed] [Google Scholar]
- Helin K, Harlow E, Fattaey A (1993) Inhibition of E2F‐1 transactivation by direct binding of the retinoblastoma protein. Mol. Cell. Biol. 13, 6501–6508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Herbert BS, Wright WE, Shay JW (2002) p16 (INK4a) inactivation is not required to immortalize human mammary epithelial cells. Oncogene 21, 7897–7900. [DOI] [PubMed] [Google Scholar]
- Holt SE, Aisner DL, Shay JW, Wright WE (1997) Lack of cell cycle regulation of telomerase activity in human cells. Proc. Natl. Acad. Sci. USA 94, 10687–10692. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Holt SE, Wright WE, Shay JW (1996) Regulation of telomerase activity in immortal cell lines. Mol. Cell. Biol. 16, 2932–2939. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hudson AE, Feng WC, Delostrinos CF, Carmean N, Bassuk JA (2005) Spreading of embryologically distinct urothelial cells is inhibited by SPARC. J. Cell. Physiol. 202, 453–463. [DOI] [PubMed] [Google Scholar]
- Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM, Reznikoff CA (1999) p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res. 59, 2957–2964. [PubMed] [Google Scholar]
- Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori K, Itoh N, Yamada H, Terachi T, Yoshida O (1997) Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J. Natl. Cancer Inst. 89, 724–730. [DOI] [PubMed] [Google Scholar]
- Kirk D, Kagawa S, Vener G, Narayan KS, Ohnuki Y, Jones LW (1985) Selective growth of normal adult human urothelial cells in serum‐free medium. In Vitro Cell. Dev. Biol. 21, 165–171. [DOI] [PubMed] [Google Scholar]
- Kiyono T, Foster SA, Koop JI, McDougall JK, Galloway DA, Klingelhutz AJ (1998) Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 396, 84–88. [DOI] [PubMed] [Google Scholar]
- McMurray HR, McCance DJ (2003) Human papillomavirus type 16, E6 activates TERT gene transcription through induction of c‐Myc and release of USF‐mediated repression. J. Virol. 77, 9852–9861. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McMurray HR, McCance DJ (2004) Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16, E6/E7. J. Virol. 78, 5698–5706. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Moll R, Achtstatter T, Becht E, Balcarova‐Stander J, Ittensohn M, Franke WW (1988) Cytokeratins in normal and malignant transitional epithelium. Maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines. Am. J. Pathol. 132, 123–144. [PMC free article] [PubMed] [Google Scholar]
- O’Hare MJ, Bond J, Clarke C, Takeuchi Y, Atherton AJ, Berry C, Moody J, Silver AR, Davies DC, Alsop AE, Neville AM, Jat PS (2001) Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc. Natl. Acad. Sci. USA 98, 646–651. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Petzoldt JL, Leigh IM, Duffy PG, Masters JR (1994) Culture and characterisation of human urothelium in vivo and in vitro . Urol. Res. 22, 67–74. [DOI] [PubMed] [Google Scholar]
- Priest JH (1997) General cell culture principles and Fibroblast Culture In: Barch MJ, Knutsen T, Spurbeck JL, eds. The AGT Cytogenetics Laboratory Manual, pp. 173–197. Philadelphia: Lippincott‐Raven Press. [Google Scholar]
- Puthenveettil JA, Burger MS, Reznikoff CA (1999) Replicative senescence in human uroepithelial cells. Adv. Exp. Med. Biol. 462, 83–91. [DOI] [PubMed] [Google Scholar]
- Reznikoff CA, Belair C, Savelieva E, Zhai Y, Pfeifer K, Yeager T, Thompson KJ, Devries S, Bindley C, Newton MA (1994) Long‐term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7‐, but not E6‐, immortalized human uroepithelial cells. Genes Dev. 8, 2227–2240. [DOI] [PubMed] [Google Scholar]
- Reznikoff CA, Loretz LJ, Johnson MD, Swaminathan S (1986) Quantitative assessments of the cytotoxicity of bladder carcinogens towards cultured normal human uroepithelial cells. Carcinogenesis 7, 1625–1632. [DOI] [PubMed] [Google Scholar]
- Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, Stadler WM (1996a) Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16, E6, but not E7, transformed human uroepithelial cells. Cancer Res. 56, 2886–2890. [PubMed] [Google Scholar]
- Reznikoff CA, Belair CD, Yeager TR, Savelieva E, Blelloch RH, Puthenveettil JA, Cuthill S (1996b) A molecular genetic model of human bladder cancer pathogenesis. Semin. Oncol. 23, 571–584. [PubMed] [Google Scholar]
- Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H, De Luca M, Catricala C, O'Toole KM (2002) A two‐stage, p16 (INK4A) – and p53‐dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol. Cell. Biol. 22, 5157–5172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD (2001) Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409, 633–637. [DOI] [PubMed] [Google Scholar]
- Savelieva E, Belair CD, Newton MA, Devries S, Gray JW, Waldman F, Reznikoff CA (1997) 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16, E7 transformed human uroepithelial cells. Oncogene 14, 551–560. [DOI] [PubMed] [Google Scholar]
- Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129–1136. [DOI] [PubMed] [Google Scholar]
- Shaffer LG, Tommerup N (2005) ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger Press. [Google Scholar]
- Shaw NJ, Georgopoulos NT, Southgate J, Trejdosiewicz LK (2005) Effects of loss of p53 and p16 function on life span and survival of human urothelial cells. Int. J. Cancer 116, 634–639. [DOI] [PubMed] [Google Scholar]
- Shay JW, Wright WE, Brasiskyte D, Van der Haegen BA (1993) E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene 8, 1407–1413. [PubMed] [Google Scholar]
- Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK (1994) Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab. Invest. 71, 583–594. [PubMed] [Google Scholar]
- Stanley AJ, Banks RE, Southgate J, Selby PJ (1995) Effect of cell density on the expression of adhesion molecules and modulation by cytokines [see comments]. Cytometry 21, 338–343. [DOI] [PubMed] [Google Scholar]
- Varley C, Hill G, Pellegrin S, Shaw NJ, Selby PJ, Trejdosiewicz LK, Southgate J (2005) Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro . Exp. Cell Res. 306, 216–229. [DOI] [PubMed] [Google Scholar]
- Vaziri H, Benchimol S (1998) Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8, 279–282. [DOI] [PubMed] [Google Scholar]
- Veldman T, Horikawa I, Barrett JC, Schlegel R (2001) Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16, E6 oncoprotein. J. Virol. 75, 4467–4472. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Veldman T, Liu X, Yuan H, Schlegel R (2003) Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. USA 100, 8211–8216. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vieten L, Belair CD, Savelieva L, Julicher K, Brocker F, Bardenheuer W, Schutte J, Opalka B, Reznikoff CA (1998) Minimal deletion of 3p13 → 14.2 associated with immortalization of human uroepithelial cells. Genes Chromosomes Cancer 21, 39–48. [DOI] [PubMed] [Google Scholar]
- Yang J, Chang E, Cherry AM, Bangs CD, Oei Y, Bodnar A, Bronstein A, Chiu CP, Herron GS (1999) Human endothelial cell life extension by telomerase expression. J. Biol. Chem. 274, 26141–26148. [DOI] [PubMed] [Google Scholar]
- Zhang D, Kosman J, Carmean N, Grady R, Bassuk JA (2006) FGF‐10 and its receptor exhibit bidirectional paracrine targeting to urothelial and smooth muscle cells in the lower urinary tract. Am. J. Physiol. Renal Physiol. 291, F481–F494. [DOI] [PubMed] [Google Scholar]
